Nutrient and metabolite interventions for neurodegenerative diseases show inconsistent clinical translation

Photo by KOMMERS / Unsplash

Frontiers in Medicine Published June 3, 2026 Medically reviewed June 3, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider that nutrient interventions for neurodegenerative diseases lack consistent clinical evidence.

This is a narrative review examining the potential role of nutrients like vitamins, minerals, polyunsaturated fatty acids, phytochemicals, and newer metabolites from marine and microbiome sources for several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. The authors synthesize evidence from in-vitro and preclinical models, noting that while these interventions show biological plausibility, translation to consistent clinical benefit remains uncertain. Key limitations highlighted by the authors include heterogeneity in study design, issues with bioavailability, blood-brain barrier penetration, dosing strategies, and disease stage. The review does not report specific pooled effect sizes, sample sizes, or clinical trial outcomes. Given the reliance on preclinical data, the authors caution that current evidence is insufficient to support routine clinical use. Practice relevance is not established, and the review underscores the need for more rigorous human studies to clarify any potential role of these nutrients in neurodegenerative disease management.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

The Neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), Multiple sclerosis (MS), and Amyotrophic lateral sclerosis (ALS) are a growing health burden across the world with minimal disease-modifying treatment and therapy. It is emerging that neurodegeneration is not only a progressive loss of neurons, but also a nutrient-sensitive systems-level dysfunction that takes the form of redox imbalance, chronic neuroinflammation, mitochondrial dysfunction, impaired proteostasis, and synaptic loss. The aging brain are more prone to metabolic vulnerability, and subclinical deficiencies in essential nutrients and bioactive dietary compounds may exacerbate cellular stress responses that contribute to disease progression. It summarizes the existing data on the effects of nutrients like vitamins, minerals, polyunsaturated fatty acids, and various phytochemicals in modulating neuronal homeostasis by regulating oxidative signaling, inflammatory cascades, mitochondrial resilience, autophagy, and synaptic plasticity. These nutrient-mediated effects collectively influence neuronal survival, synaptic integrity, and cognitive function by affecting disease susceptibility and progression. Additionally newer metabolites of the marine and microbiome act as new neuroactive agents. The evidence from in-vitro and preclinical models, translation to clinical benefit remains inconsistent due to heterogeneity in study design, bioavailability, blood- brain barrier penetration, dosing strategies and disease stage. This review highlights emerging potential of precision nutrition frameworks that integrate nutrigenomics, metabolomics, and microbiome interactions, and individualized metabolic profiling to enable context-dependent and stage-specific interventions. Moreover, conceptualizing neurodegeneration as a nutrient-sensitive, systems level disorder, propose a mechanistically informed and integrative approach that combine targeted nutritional strategies with pharmacological and lifestyle therapies to more effectively modify neurodegenerative trajectories.